Subsequently, a 24 month follow-up study of ACT34-CMI patients revealed that weekly angina frequency at 24 months was significantly reduced in patients treated with both low- and high-dose CD34+ cells compared with placebo-treated patients. The gene discussed is CD34; the disease is angina pectoris.